Company Overview and Q3 Highlights
ALX Oncology Holdings (NASDAQ: ALXO) is a clinical-stage biotech focused on cancer immunotherapy, best known for its lead CD47-blocking drug candidate evorpacept. The company’s third-quarter results showcased promising clinical progress alongside improving financial discipline. In the Phase 2 ASPEN-06 trial for HER2-positive gastric/gastroesophageal cancer, evorpacept (combined with standard therapies) achieved a 40.3% objective response rate versus 26.6% in the control arm ([1]). This first-ever positive randomized data in a solid tumor for a CD47-targeted therapy confirms evorpacept’s unique safety and mechanism of action advantages seen to date ([2]) ([3]). Management considers these results a key growth milestone, validating evorpacept’s potential to enhance existing cancer treatments ([2]).
On the financial side, Q3 2025 showed a sharply narrower net loss of $22.1 million (or $0.41 per share) compared to a $30.7 million loss ($0.58 per share) in Q3 2024 ([4]). This improvement was driven by major cost reductions – R&D expenses fell to $17.4 million in Q3 2025 from $26.5 million a year earlier ([4]), as the company implemented pipeline prioritization and efficiency measures. G&A expenses also declined to $5.1 million from $6.1 million ([4]). Thanks to these cuts, non-GAAP net loss (excluding stock comp and loan accretion) improved to $19.6 million, from $23.7 million in Q3 2024 ([4]). In short, ALXO is advancing its pipeline while tightening its belt, a combination that underpins the hidden growth potential indicated by Q3 results.
Dividend Policy and Yield
ALX Oncology does not pay any dividend, which is typical for a development-stage biotech with no product revenue. The company has never declared a cash dividend since inception, and it intends to retain any future earnings to fund research and development ([3]). In fact, management explicitly notes they do not anticipate paying dividends in the foreseeable future, so shareholders should expect returns only through stock price appreciation ([3]) ([3]). Traditional income metrics like dividend yield or payout ratio are therefore not applicable – ALXO’s yield is 0%. Likewise, industry metrics such as FFO or AFFO (used for REITs) have no relevance here, as ALXO generates no operating funds from which to pay dividends. Investors in ALXO are betting on capital gains driven by successful drug development rather than any near-term income distribution.
Balance Sheet, Leverage and Coverage
ALXO’s balance sheet reflects its status as a cash-burning R&D enterprise. As of Q3 2025, the company held $66.5 million in cash, equivalents and investments ([4]), down from $162.6 million a year earlier ([1]) after funding ongoing trials. Crucially, management estimates this cash runway will fund operations into Q1 2027 ([4]), which covers several upcoming clinical milestones (discussed later). The cash burn has been moderated by cost cuts – for perspective, net losses in 2024 were $160.8 million, which declined to $134.9 million in 2025 ([3]). With roughly $66M on hand, ALXO can cover its projected expenditures for about five more quarters, assuming recent quarterly burn rates in the low ~$20 millions continue. This runway gives the company breathing room to advance trials without an immediate financing need, although it ultimately remains reliant on external capital (either partnership or fundraising) to reach profitability ([3]).
90-day unconditional refund — test the playbook risk-free
Leverage: The company carries minimal debt relative to its equity. In late 2022, ALX Oncology secured a term loan facility of up to $100 million from Oxford Finance and (the now-defunct) Silicon Valley Bank ([5]). At closing, it drew an initial $10 million from a $50 million first tranche, leaving $40 million available (which expired undrawn at 2023’s end) ([5]). The remaining $50 million of the facility was structured in milestone-dependent tranches (and at lender discretion) for future use ([5]). As of the latest filings, only about $10 million of debt is outstanding, recorded at ~$9.5 million net of issuance costs ([3]). This loan carries a floating interest rate of SOFR + 6.25% (minimum 8.58%) ([3]) – given today’s SOFR near 5%, ALXO is paying roughly 11–12% annual interest on the debt. That equates to <$1.2 million interest per year, a modest burden relative to its cash reserves.
Maturities and coverage: The term loan is interest-only through late 2025, with principal repayments starting December 1, 2025 ([3]). The loan will amortize monthly thereafter and is scheduled to mature in October 2027 ([3]). There are no financial covenants or warrant kickers on this debt, reducing potential constraints ([5]). With the current cash on hand, ALXO has more than enough liquidity to cover interest payments and the upcoming principal installments in 2026. In essence, interest coverage is not an immediate concern – while the company has no earnings, its cash buffer can comfortably service the relatively small debt obligations for the foreseeable future. However, if additional debt were drawn or cash reserves dwindle faster than expected, the situation would change. It’s worth noting that the loan is secured against substantially all assets (except intellectual property) ([3]), so stakeholders must monitor the company’s ability to maintain its cash runway. At present, though, ALXO’s capital structure is equity-heavy and low-leverage, which is prudent given its stage of development.
Valuation and Comparative Metrics
Valuing a company like ALX Oncology is challenging using conventional multiples, since it has no positive earnings or revenue to anchor a P/E or P/S ratio. Instead, investors often look at tangible book value and enterprise value (EV) relative to the pipeline prospects. ALXO’s stock price has declined drastically over the past two years, and currently trades around $1–1.50 per share (it was $1.18 in early November 2025) ([4]). At ~$1.20/share, the market capitalization is roughly $60–70 million, which is striking given the company’s last reported cash of $66.5 million. In effect, the enterprise value is near-zero – for example, at $1.65/share (earlier this year), ALXO’s market cap was ~$88 million while EV was only ~$22 million after backing out cash ([6]). With the stock even lower now, EV is just a few million dollars. This implies the market assigns almost no value to ALXO’s pipeline beyond its cash holdings.
The AI Doom Loop: Jim Rickards' Shocking Prediction
A market crash like you've never seen — as soon as July 15, 2025. Read the must-see plan to protect your savings and family.
— Market Danger
From another angle, ALXO trades at about 1.3× book value (P/B). As of year-end 2024, shareholders’ equity was $113.6 million ([3]) ([3]), but by Q3 2025 equity likely fell to ~$45 million due to cumulative losses and cash usage ([4]). Even so, the stock price indicates a P/B near 1x or below on the latest book, reflecting deep skepticism. Such a “cash-box” valuation is often seen in small biotechs when investors doubt the pipeline’s success. For context, larger pharmaceutical companies previously paid hefty sums for CD47 programs (e.g. Pfizer’s $2.3 billion acquisition of Trillium, Gilead’s $4.9 billion buyout of Forty Seven), but ALXO’s market value today is a tiny fraction of those deals. The difference is that ALXO is still in clinical trials and unproven at a commercial scale. However, the hidden potential here is that if evorpacept’s efficacy and safety advantages are confirmed in larger studies, ALXO’s valuation could recalibrate sharply upwards. In essence, the stock is priced as if the pipeline will fail or face heavy dilution – any signs to the contrary (positive trial data, partnerships, etc.) could unlock significant upside.
Risks and Red Flags
Despite the optimistic data signals, ALX Oncology carries significant risks typical of an early-stage biotech. First and foremost is clinical and regulatory risk: evorpacept and the new ALX2004 ADC must clear many hurdles before any FDA approval or revenue. Positive Phase 2 results are encouraging, but larger Phase 3 trials could yield different outcomes. There is no guarantee that the higher response rates seen in a subset of gastric cancer patients will translate into statistically significant benefits in broader populations or other cancers. The company’s strategy now includes selecting patients with high CD47 expression (where evorpacept performed best) ([4]) ([4]), but this biomarker-driven approach could narrow the target market or add complexity (e.g. developing a diagnostic test). Scientific risk remains that the CD47 pathway, though promising, could encounter problems – for example, competitors’ CD47 drugs have faced setbacks like toxicities (anemia) or trial holds in the past ([3]) ([3]). While evorpacept’s engineered inactive Fc design aims to avoid those blood toxicities ([3]) ([3]), long-term safety in larger populations is still being evaluated.
Another major risk is financial sustainability. ALXO has no revenue and does not expect any product sales for years to come ([3]). It funds operations through cash reserves and periodic capital raises ([3]). The Q3 2025 runway estimate (into early 2027) assumes the company sticks to a leaner budget; any trial expansions, new programs, or delays could accelerate cash burn. When the cash runway runs out, dilution risk is high – raising substantial funds at the current low share price would significantly dilute existing shareholders. The last equity raise was an oversubscribed offering in late 2023 at $6.38/share ([2]). Today’s price near $1 is ~80% lower, meaning ALXO would have to issue many more shares to raise an equivalent sum, unless the stock recovers. This dynamic creates a vicious circle: the market is wary of future dilution, which keeps the stock depressed, which in turn makes any new financing more painful. Management could also seek non-dilutive funds (e.g. partnerships or drawing on loan tranches), but those come with their own trade-offs (sharing profits, debt costs, etc.). Notably, the loan agreement’s additional $40M tranche expired unused, suggesting the company preferred equity capital when it was available – going forward, tapping the remaining debt (tied to milestones) is an option if conditions are met.
3 Stocks to Own Before Oct 16
The payment rails, the mint, and the platform — the three plays that could define America’s new money.
There are also operational red flags to monitor. The company has undergone leadership changes – for instance, in Q3 2025 ALXO appointed board member Dr. Barbara Klencke as interim Chief Medical Officer ([4]). While Dr. Klencke is experienced, the transition indicates that a permanent CMO was not in place, which could temporarily disrupt clinical strategy. ALXO also “realigned” its team and pipeline in 2023 ([2]), hinting at possible downscoping of programs or layoffs to conserve cash. Such moves can be double-edged: they extend the runway but might slow down or limit the breadth of R&D. Another risk is competition – the immuno-oncology field is crowded, and many large players (Pfizer, Gilead, Roche, etc.) are developing their own agents or could quickly move into ALXO’s niche ([3]). If a competing therapy (e.g. another CD47 blocker or a different approach for HER2 cancers) succeeds first, it could erode ALXO’s opportunity. Lastly, the stock’s low price itself is a concern: should it trade below $1 for an extended period, NASDAQ compliance issues could arise (though ALXO has managed to stay slightly above that threshold recently). In summary, investors face the high-risk, high-reward profile common to small biotechs – where binary clinical outcomes and financing events can dramatically swing the prospects.
Outlook and Open Questions
Going forward, key catalysts will reveal whether ALX Oncology’s hidden growth potential materializes. One near-term event is the initiation of the Phase 2 ASPEN-09 trial in breast cancer (HER2-positive) by Q4 2025 ([4]). This study will deliberately enroll patients with high CD47-expression tumors, applying the learnings from gastric cancer. An interim data readout for ASPEN-09 is expected in Q3 2026 ([4]). Positive results here – demonstrating that evorpacept can enhance outcomes in breast cancer as it did in gastric cancer – would be strong validation of the drug’s broader applicability. Another upcoming milestone is ALX2004, the company’s second pipeline asset. ALX2004 is a novel EGFR-targeted antibody-drug conjugate (ADC) currently in a Phase 1 dose-escalation trial ([4]). Initial safety data from ALX2004’s trial is anticipated in the first half of 2026 ([4]). If this ADC shows a favorable safety profile (as preclinical data suggest) and early signs of anti-tumor activity, it could open a new growth avenue beyond evorpacept. It’s essentially a pipeline within a pipeline, since ADCs are a hot area in oncology – success could attract partnerships or investor interest, whereas setbacks would narrow ALXO’s focus back to CD47 alone.
Open questions: A critical question is whether ALXO will partner or go solo for late-stage development. Thus far, the company has retained full ownership of evorpacept, but as trials progress to Phase 3, the costs and complexity increase. Management’s ability to secure a partnership with a larger pharma (ideally providing upfront cash and R&D support) could be a game-changer for funding and validation. On the other hand, partnering often means giving up a share of future profits – a tough call if one believes evorpacept could be a blockbuster. Another question is when regulators might allow an accelerated path. The ASPEN-06 gastric cancer data were impressive, but likely not enough for approval on their own. Will ALXO need to run a full Phase 3 in that indication, or could they leverage the biomarker finding (CD47-high patients) to design a targeted pivotal trial? The regulatory strategy is still unfolding. Additionally, how large is the true market for a CD47-targeted adjuvant therapy? If they focus on CD47-high expressers, that sub-population must be defined and accessible via testing. Meanwhile, competitors’ moves bear watching – for instance, if Pfizer or Gilead’s CD47 programs (acquired via Trillium and Forty Seven) overcome their issues and return strong results, ALXO will need to differentiate itself or race to niche approvals ([3]). Conversely, if competitors continue to stumble, ALXO could become the leader in resurrecting the CD47 immunotherapy approach.
Finally, financing strategy remains an open question. With an estimated runway to early 2027, ALXO has bought itself time, but not a free pass to commercialization. Investors will be looking for how the company plans to bridge from current cash to any eventual drug approval. Will it be through additional equity raises (hopefully at higher share prices if data is positive), through debt (the remaining loan facility or new credit, though biotech debt is limited without revenue), or via a strategic transaction? At the current low valuation, ALXO itself could become a takeover target if a larger oncology player sees an opportunity – acquiring the company (and evorpacept) for even a few hundred million would be relatively cheap compared to past CD47 deal values. However, management and shareholders may prefer to wait for data that better reflects the drug’s value. In essence, ALX Oncology’s future is at a crossroads: the next 12–18 months of trial results and business development decisions will determine whether the hidden growth potential highlighted by Q3’s progress translates into tangible returns. Investors should watch these developments closely, as they will answer whether ALXO can evolve from a cash-burning hopeful into a successful, value-generating biotech – or whether it might need to seek a larger partner to realize the full promise of its science. ([3]) ([3])
Sources
- https://stocktitan.net/news/ALXO/alx-oncology-reports-third-quarter-2024-financial-results-and-tpbfep5hepzh.html
- https://globenewswire.com/news-release/2023/11/13/2779425/0/en/ALX-Oncology-Reports-Third-Quarter-2023-Financial-Results-and-Provides-Corporate-Update.html
- https://sec.gov/Archives/edgar/data/1810182/000095017025034761/alxo-20241231.htm
- https://marketscreener.com/news/alx-oncology-reports-third-quarter-2025-financial-results-and-provides-corporate-update-ce7d5fdada8ef125
- https://ir.alxoncology.com/news-releases/news-release-details/alx-oncology-enters-100-million-loan-facility-agreement-oxford
- https://gurufocus.com/stock/ALXO/summary
For informational purposes only; not investment advice.